This article is more than 5 years old. Information may no longer be current.

VIDEO: Flublok demonstrates superior efficacy over IIV

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

BALTIMORE — Lisa M. Dunkle, MD, chief medical officer and head of clinical research at Protein Sciences Corp., discusses results from a recent phase 3 trial that evaluated the safety and immunogenicity of a recombinant quadrivalent influenza vaccine, Flublok, which was compared with an egg-derived inactivated influenza vaccine, or IIV. Carried out during the 2014-2015 influenza season, the study showed that Flublok was 30% to 40% more effective in preventing influenza compared with IIV.

Results from the trial were reported at the Annual Conference on Vaccine Research, hosted by the National Foundation for Infectious Diseases.

Disclosure: Dunkle is employed by and owns stock, stock options or bonds from Protein Sciences Corp.